Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Mizuho Securities Downgrades Eagle Pharmaceuticals (EGRX) to Neutral; Stock to Plateau Post-Analyst Day
November 16, 2016 6:28 AM ESTMizuho Securities downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from Buy to Neutral while maintaining a $78 price target.
Analyst Irina Koffler commented, "We expect the stock to plateau after the Analyst Day due to lighter catalyst flow, weaker Treanda/Bendeka revenues reported by partner... More



